Role of Adjuvant Chemoradiotherapy for Ampulla of Vater Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 2, 2009, Pages 436-441

  Kim, Kyubo ^a   Chie, Eui Kyu ^a   Jang, Jin Young ^a   Kim, Sun Whe ^a   Oh, Do Youn ^a   Im, Seock Ah ^a   Kim, Tae You ^a   Bang, Yung Jue ^a   Ha, Sung W ^a,b  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Adjuvant chemoradiotherapy; Ampulla of Vater cancer

Indexed keywords

5-FLUOROURACIL; ADJUVANT CHEMORADIOTHERAPY; AMPULLA OF VATER; AMPULLA OF VATER CANCER; CHEMORADIOTHERAPY; COX PROPORTIONAL HAZARD MODEL; HISTOLOGIC DIFFERENTIATION; LOCOREGIONAL CONTROL; LYMPH NODE; NODAL METASTASIS; OVERALL SURVIVAL; OVERALL SURVIVAL RATES; POSTOPERATIVE RADIOTHERAPY; RELAPSE-FREE SURVIVAL RATES; REST PERIODS; TOTAL DOSE; TUMOR BED;

DISEASE CONTROL;

FLUOROURACIL; FOLINIC ACID; MITOMYCIN C; UFT;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; FEMALE; GROUPS BY AGE; HISTOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MORBIDITY; MULTIVARIATE ANALYSIS; NAUSEA AND VOMITING; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RADIATION DOSE; SURGICAL TECHNIQUE; UNIVARIATE ANALYSIS; VATER PAPILLA CARCINOMA;

ADULT; AGE FACTORS; AGED; AMPULLA OF VATER; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; COMMON BILE DUCT NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; LYMPHATIC IRRADIATION; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 69549135404     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.11.067     Document Type: Article

References (25)

1. Yeo C.J., Sohn T.A., Cameron J.L., et al. Periampullary adenocarcinoma: Analysis of 5-year survivors. Ann Surg 227 (1998) 821-831
2. Michelassi F., Erroi F., Dawson P.J., et al. Experience with 647 consecutive tumors of the duodenum, ampulla, head of the pancreas, and distal common bile duct. Ann Surg 210 (1989) 544-554
3. Howe J.R., Klimstra D.S., Moccia R.D., et al. Factors predictive of survival in ampullary carcinoma. Ann Surg 228 (1998) 87-94
4. Monson J.R., Donohue J.H., McEntee G.P., et al. Radical resection for carcinoma of the ampullar of Vater. Arch Surg 126 (1991) 353-357
5. Neoptolemos J.P., Talbot I.C., Carr-Locke D.L., et al. Treatment and outcome in 52 consecutive cases of ampullary carcinoma. Br J Surg 74 (1987) 957-961
6. Shutze W.P., Sack J., and Aldrete J.S. Long-term follow-up of 24 patients undergoing radical resection for ampullary carcinoma, 1953 to 1988. Cancer 66 (1990) 1717-1720
7. Talamini M.A., Moesinger R.C., Pitt H.A., et al. Adenocarcinoma of the ampulla of Vater: A 28-year experience. Ann Surg 225 (1997) 590-600
8. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230 (1999) 776-782
9. Willett C.G., Warshaw A.L., Convery K., et al. Patterns of failure after pancreaticoduodenectomy for ampullary carcinoma. Surg Gynecol Obstet 176 (1993) 33-38
10. Lee J.H., Whittington R., Williams N.N., et al. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys 47 4 (2000) 945-953
11. Mehta V.K., Fisher G.A., Ford J.M., et al. Adjuvant chemoradiotherapy for "unfavorable" carcinoma of the ampulla of Vater. Arch Surg 136 (2001) 65-69
12. Sikora S.S., Balachandran P., Dimri K., et al. Adjuvant chemo-radiotherapy in ampullary cancers. Eur J Surg Oncol 31 (2005) 158-163
13. Bhatia S., Miller R.C., Haddock M.G., et al. Adjuvant therapy for ampullary carcinomas: The Mayo Clinic experience. Int J Radiat Oncol Biol Phys 66 (2006) 514-519
14. Kaplan E.L., and Meier P.I. A nonparametric estimation from incomplete observations. J Am Statics Assoc 53 (1958) 457-481
15. American Joint Committee on Cancer. Cancer staging handbook. 6th ed (2002), Springer- Verlag, New York p. 107-112
16. Cox J.D., Stetz J., and Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31 (1995) 1341-1346
17. Miller A.B., Hoogstraten B., Staquet M., et al. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
18. Barton R.M., and Copeland III E.M. Carcinoma of the ampulla of Vater. Surg Gynecol Obstet 156 (1983) 297-301
19. Kopelson G. Curative surgery for adenocarcinoma of the pancreas/ampulla of Vater: The role of adjuvant pre or postoperative radiation therapy. Int J Radiat Oncol Biol Phys 9 (1983) 911-915
20. Todoroki T., Koike N., Morishita Y., et al. Patterns and predictors of failure after curative resections of carcinoma of the ampulla of Vater. Ann Surg Oncol 10 (2003) 1176-1183
21. Beger H.G., Treitschke F., Gansauge F., et al. Tumor of the ampulla of Vater: Experience with local or radical resection in 171 consecutively treated patients. Arch Surg 134 (1999) 526-532
22. Scheithauer W. Review of gemcitabine in biliary tract carcinoma. Semin Oncol 29 Suppl. 20 (2002) 40-45
23. Andre T., Tournigand C., Rosmorduc O., et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: A GERCOR study. Ann Oncol 15 (2004) 1339-1343
24. Cho J.Y., Paik Y.H., Chang Y.S., et al. Capecitabine combined with gemcitabine as first-line treatment in patients with advanced/metastatic biliary tract carcinoma. Cancer 104 (2005) 2753-2758
25. Kim S.T., Park J.O., Lee J., et al. A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 106 (2006) 1339-1346